{"id":"lonidamine","rwe":[{"pmid":"41843844","year":"2026","title":"Proteasome Inhibition as a Cancer Type-Specific Off-Target Effect of Everolimus in Cancer Cells.","finding":"","journal":"Biochemistry. Biokhimiia","studyType":"Clinical Study"},{"pmid":"41822778","year":"2026","title":"Lonidamine-1,3,4-oxadiazole derivatives with antiproliferative effects on HCT116 colon cancer cell lines: biological evaluation, ADMET, and computational studies.","finding":"","journal":"RSC advances","studyType":"Clinical Study"},{"pmid":"41787925","year":"2026","title":"Lonidamine ameliorates MASH by reducing SREBP1 and inhibiting the MAPK pathway.","finding":"","journal":"Acta biochimica et biophysica Sinica","studyType":"Clinical Study"},{"pmid":"41766177","year":"2026","title":"Design and Synthesis of Novel Lonidamine-N-Heterocyclic Derivatives With Potent Anticancer Activity Against Colorectal Cancer Cells.","finding":"","journal":"Drug development research","studyType":"Clinical Study"},{"pmid":"41660127","year":"2026","title":"NIR-II imaging-guided nanoplatform for synergistic mitochondria-targeted pyroptosis and macrophage reprogramming immunotherapy.","finding":"","journal":"Materials today. Bio","studyType":"Clinical Study"}],"tags":[{"label":"lonidamine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Mitochondrial pyruvate carrier 2","category":"target"},{"label":"MPC2","category":"gene"},{"label":"L01XX07","category":"atc"},{"label":"Active","category":"status"},{"label":"Malignant tumor of lung","category":"indication"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Antispermatogenic Agents","category":"pharmacology"},{"label":"Contraceptive Agents","category":"pharmacology"},{"label":"Contraceptive Agents, Male","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"},{"label":"Radiation-Sensitizing Agents","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"},{"label":"Trypanocidal Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"doridamina","offLabel":[],"synonyms":["doridamina","lonidamine","diclondazolic acid"],"timeline":[],"approvals":[],"brandName":"Doridamina","ecosystem":[{"indication":"Malignant tumor of lung","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Mitochondrial pyruvate carrier 2","targets":[{"gene":"MPC2","source":"DrugCentral","target":"Mitochondrial pyruvate carrier 2","protein":"Mitochondrial pyruvate carrier 2"}],"modality":"Small Molecule","drugClass":"lonidamine","explanation":"Think of it like a car engine - the mitochondrial pyruvate carrier 2 is like the fuel injector, and Doridamina blocks it from working properly. This can slow down the growth of cancer cells, which need a lot of energy to multiply. By blocking this fuel source, Doridamine can help to slow down the growth of tumors.","oneSentence":"Doridamina works by inhibiting the mitochondrial pyruvate carrier 2, which is involved in the production of energy within cells.","technicalDetail":"Doridamina specifically inhibits the mitochondrial pyruvate carrier 2 (MPC2), a protein complex that plays a crucial role in the transport of pyruvate into mitochondria, where it is converted into acetyl-CoA and enters the citric acid cycle, generating energy for the cell."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1598","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LONIDAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LONIDAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:24:06.577021","biosimilars":[],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"altretamine","drugSlug":"altretamine","fdaApproval":"1990-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"denileukin diftitox","drugSlug":"denileukin-diftitox","fdaApproval":"1999-02-05","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eribulin","drugSlug":"eribulin","fdaApproval":"2010-11-15","patentExpiry":"Jul 8, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"lonidamine","indications":{"approved":[{"name":"Malignant tumor of lung","source":"DrugCentral","snomedId":363358000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"altretamine","brandName":"altretamine","genericName":"altretamine","approvalYear":"1990","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"denileukin-diftitox","brandName":"denileukin diftitox","genericName":"denileukin diftitox","approvalYear":"1999","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00435448","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia","status":"TERMINATED","sponsor":"Threshold Pharmaceuticals","startDate":"2005-06","conditions":["Benign Prostatic Hyperplasia","Enlarged Prostate"],"enrollment":480,"completionDate":"2006-12"},{"nctId":"NCT00237536","phase":"PHASE2","title":"Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia","status":"TERMINATED","sponsor":"Threshold Pharmaceuticals","startDate":"2005-06","conditions":["Benign Prostatic Hyperplasia"],"enrollment":240,"completionDate":"2006-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"U78804BIDR","CHEBI":"CHEBI:50138","INN_ID":"4324","UMLSCUI":"C0065175","ChEMBL_ID":"CHEMBL1257030","KEGG_DRUG":"D07257","DRUGBANK_ID":"DB06266","PUBCHEM_CID":"39562","IUPHAR_LIGAND_ID":"12601","MESH_SUPPLEMENTAL_RECORD_UI":"C016371"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":548,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XX07","allCodes":["L01XX07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb","pmid":"41843844","title":"Proteasome Inhibition as a Cancer Type-Specific Off-Target Effect of Everolimus in Cancer Cells.","journal":"Biochemistry. Biokhimiia"},{"date":"2026 Mar 9","pmid":"41822778","title":"Lonidamine-1,3,4-oxadiazole derivatives with antiproliferative effects on HCT116 colon cancer cell lines: biological evaluation, ADMET, and computational studies.","journal":"RSC advances"},{"date":"2026 Mar 5","pmid":"41787925","title":"Lonidamine ameliorates MASH by reducing SREBP1 and inhibiting the MAPK pathway.","journal":"Acta biochimica et biophysica Sinica"},{"date":"2026 Apr","pmid":"41766177","title":"Design and Synthesis of Novel Lonidamine-N-Heterocyclic Derivatives With Potent Anticancer Activity Against Colorectal Cancer Cells.","journal":"Drug development research"},{"date":"2026 Apr","pmid":"41660127","title":"NIR-II imaging-guided nanoplatform for synergistic mitochondria-targeted pyroptosis and macrophage reprogramming immunotherapy.","journal":"Materials today. Bio"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doridamina, also known as Lonidamine, is a small molecule drug that targets the mitochondrial pyruvate carrier 2. It is classified as a lonidamine drug and has been approved for the treatment of malignant tumors of the lung. The commercial status of Doridamina is currently unknown, and it is not clear if it is patented or available as a generic medication. As a pharmaceutical professional, it is essential to consider the potential safety implications of using this drug, including any unknown side effects or interactions. Further research is needed to fully understand the pharmacokinetics and pharmacodynamics of Doridamina.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}